Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability ...
H. Lundbeck a déclaré jeudi que l'Agence européenne des médicaments a autorisé l'utilisation élargie de son médicament contre ...
Le médicament Rxulti de la société pharmaceutique danoise Lundbeck a été autorisé dans l'UE pour le traitement de la ...
GlobalData on MSN9d
Bloom Science’s obesity therapy sustains weight loss after final dosingThe live biotherapeutic elicited a 2.3% drop in weight loss in patients, which was maintained for weeks after dosing had ...
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability ...
Irish vet, Patricia Reilly, has joined President of the European Commission, Ursula von der Leyen's cabinet as agriculture ...
The Independent Data Monitoring Committee overseeing the interim analysis of Study 1 of the Essential3 program has provided Praxis with the ...
US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...
Praxis Precision Medicines, Inc.’s PRAX share price has dipped by 40.64%, which has investors questioning if this is right ...
While Australian researchers are paving the way in epilepsy care, findings show the significant burden on carers and parents with children living with severe epilepsies. Professor Ingrid Scheffer AO, ...
Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Praxis Precision Medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback